HC Wainwright reissued their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN - Free Report) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock.
CollPlant Biotechnologies Stock Down 3.0 %
NASDAQ:CLGN traded down $0.16 during midday trading on Friday, reaching $5.10. The stock had a trading volume of 3,637 shares, compared to its average volume of 8,637. The firm has a fifty day simple moving average of $5.32 and a two-hundred day simple moving average of $5.47. CollPlant Biotechnologies has a 12-month low of $4.22 and a 12-month high of $8.90. The stock has a market cap of $58.40 million, a P/E ratio of -8.36 and a beta of 0.24.
Hedge Funds Weigh In On CollPlant Biotechnologies
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in CollPlant Biotechnologies by 53.9% in the 1st quarter. Bank of America Corp DE now owns 7,389 shares of the company's stock valued at $52,000 after buying an additional 2,589 shares during the last quarter. UBS Group AG lifted its holdings in CollPlant Biotechnologies by 119.1% in the second quarter. UBS Group AG now owns 7,514 shares of the company's stock valued at $60,000 after acquiring an additional 4,085 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in CollPlant Biotechnologies by 11.3% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 50,150 shares of the company's stock valued at $320,000 after acquiring an additional 5,100 shares during the period. Credit Suisse AG acquired a new stake in CollPlant Biotechnologies in the fourth quarter valued at $51,000. Finally, Villere ST Denis J & Co. LLC lifted its holdings in CollPlant Biotechnologies by 2.5% in the third quarter. Villere ST Denis J & Co. LLC now owns 300,173 shares of the company's stock valued at $1,672,000 after acquiring an additional 7,450 shares during the period. 21.69% of the stock is currently owned by hedge funds and other institutional investors.
CollPlant Biotechnologies Company Profile
(
Get Free Report)
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
Recommended Stories
Before you consider CollPlant Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CollPlant Biotechnologies wasn't on the list.
While CollPlant Biotechnologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
